What the trial was testing
The DEEP-2 enrolled 435 patients with beta-thalassemia. The study was sponsored by Consorzio per Valutazioni Biologiche e Farmacologiche and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Equal performance — 55% vs. 55% iron control success at one year.
The Lancet Haematology · 2020 · NCT01825512
These findings — that iron control success on deferiprone vs. deferasirox in pediatric thalassemia — were published in the The Lancet Haematology and represent the headline result of the study.
Researchers tracked outcomes across 435 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with beta-thalassemia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Both deferiprone (Ferriprox) and deferasirox (Exjade, Jadenu) are FDA-approved for iron overload from chronic transfusions and available now. Deferiprone requires blood count monitoring for a rare but serious low-white-cell side effect. Ask a hematologist which oral chelator fits your child.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open beta-thalassemia trials
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
The goal of this clinical trial is to learn about SP-420 ability to remove iron from organs in subjects with transfusion-dependent β-thalassemia or transfusion-dependent low-risk myelodysplastic syndrome. The main questions it aims to answer are: * How efficient is SP-420 in cleaning iron from the liver? * How is the safety and tolerability of ascending doses of SP-420? Participants will: * Take medication three times weekly * Attend up to 20 site visits * Undergo MRI scans
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.